Peptide BPC-157 (5 mg) OxyPharma

Catalogue entry: Peptide BPC-157 OxyPharma. Labelled content: 5 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

BPC-157 is a research peptide containing 15 amino acids. Its literature includes gastrointestinal, vascular and musculoskeletal experiments, which explains interest in recovery discussions. Describing it as a research peptide does not itself establish a defined clinical product, an approved indication or a predictable effect in injured athletes.

What the research measured

Staresinic and colleagues studied a transected rat Achilles-tendon model in the Journal of Orthopaedic Research in 2003. Human reports include a retrospective knee-pain series by Lee and Padgett in 2021 and a two-participant safety pilot by Lee and Burgess in 2025. These small, methodologically different reports cannot supply robust estimates of efficacy or uncommon harms.

Sporting claims and limitations

Repair claims often combine BPC-157 with TB-500. Evidence for one molecule cannot establish an added benefit, interaction profile or optimal composition for REHAB MIX. Improvement in an animal injury model is different from demonstrated return to sport, durable tendon strength or reduced reinjury in people. Limited human observation also leaves important safety questions open.

Product identity and documentation

For the selected product, confirm the actual peptide identity, labelled amount and batch reference. A relevant analysis should describe the method and distinguish identity testing from a purity estimate. Research publications cannot authenticate the supplier's material or establish sterility. The product information provides a route into the evidence while retaining the difference between a laboratory hypothesis and a validated treatment.